Concise answers when you need the essentials, with deeper clinical context and transparent source links when the decision needs more scrutiny.
Search by active ingredient or familiar medicine name.
Echinacea purpurea is a herbal preparation made from purple coneflower. The selected UK tablet is registered to relieve common-cold and influenza-type symptoms based on traditional use, not proof from clinical trials. Research across varied echinacea products has not established a clear treatment benefit.
Econazole nitrate is an imidazole antifungal used locally on the skin or inside the vagina. Selected UK products are licensed for certain fungal skin infections and vaginal thrush caused by susceptible yeasts.
Eculizumab is a monoclonal antibody that blocks terminal complement activity. Under specialist supervision, it reduces complement-mediated blood-cell destruction in paroxysmal nocturnal haemoglobinuria (PNH) and blood-vessel and kidney injury in atypical haemolytic uraemic syndrome (aHUS).
Edotreotide is a somatostatin analogue used to prepare radioactive gallium-68 edotreotide for PET imaging. It helps locate certain neuroendocrine tumours in adults but does not treat cancer.
Edoxaban tosilate is an anticoagulant, sometimes called a blood thinner, that reduces harmful blood clot formation. In adults, it is licensed for certain people with nonvalvular atrial fibrillation and for treating or preventing recurrent deep vein thrombosis and pulmonary embolism.
Efanesoctocog alfa is a recombinant replacement for clotting factor VIII. It prevents and treats bleeding in people aged 2 years and over with moderate or severe haemophilia A.
Efavirenz is an NNRTI used with other antiretrovirals to treat HIV-1. It reduces viral replication but does not cure HIV and should not be used alone.
This fixed-combination antiretroviral contains three active ingredients that block HIV replication. It is licensed to maintain control of HIV-1 in selected adults whose infection is already suppressed and who have no relevant history of treatment failure or resistance.
A fixed-combination antiretroviral treatment containing three active substances that suppress HIV-1. The selected product is licensed for certain adults whose HIV is stably suppressed and not resistant to its components.
A fixed-combination antiretroviral tablet containing three components that block HIV-1 replication. It is licensed for certain adults whose HIV is stably suppressed and whose virus is not resistant to its components.
Efgartigimod alfa is a selective immunosuppressant that lowers circulating IgG antibodies, including harmful autoantibodies. Selected formulations are licensed for certain adults with generalised myasthenia gravis, and the subcutaneous formulation is also licensed for certain adults with chronic inflammatory demyelinating polyneuropathy.
A topical treatment licensed for facial hirsutism in adult women. It slows hair growth rather than removing existing hair.
Efmoroctocog alfa is a recombinant factor VIII replacement with an Fc component that helps it remain in circulation longer. It treats and helps prevent bleeding in haemophilia A.
Eftrenonacog alfa is a recombinant clotting factor IX designed to remain in circulation longer. It treats and prevents bleeding in people of all ages with haemophilia B under specialist care.
Elacestrant is an oral selective oestrogen receptor degrader used as endocrine treatment for certain advanced breast cancers. In the UK, it is licensed on its own for postmenopausal women and men whose ER-positive, HER2-negative cancer has an activating ESR1 mutation and has progressed after specified previous endocrine treatment.
Eladocagene exuparvovec is an AAV2-based gene therapy for severe aromatic L-amino acid decarboxylase (AADC) deficiency. It delivers a functioning DDC gene to brain cells, enabling AADC enzyme expression and dopamine production.
Elafibranor treats adults with primary biliary cholangitis (PBC). It is used with ursodeoxycholic acid (UDCA) when UDCA has not worked well enough, or alone when UDCA cannot be tolerated.
A fixed-combination treatment for chronic hepatitis C, principally genotypes 1 and 4, used under specialist supervision.
Eletriptan hydrobromide is a prescription-only triptan for treating the headache phase of migraine attacks in adults, with or without aura. It does not prevent migraine.
A triple CFTR modulator for cystic fibrosis caused by eligible CFTR gene variants. In the UK, it is used with a separate ivacaftor product to improve the amount and function of CFTR protein at cell surfaces.
Eliglustat tartrate is an oral substrate-reduction treatment for Gaucher disease type 1. It reduces production of the fatty substance that accumulates in affected cells. Specialist testing is needed before treatment to assess how the body metabolises it.
Elinzanetant blocks neurokinin receptors involved in temperature regulation. It is licensed for adult women with moderate to severe hot flushes and night sweats associated with menopause or caused by adjuvant endocrine therapy for breast cancer.
Elotuzumab is a humanised monoclonal antibody used with other anti-myeloma treatments for previously treated multiple myeloma.
Elranatamab is a bispecific antibody cancer treatment that helps T cells recognise and destroy multiple myeloma cells. It is licensed for use alone in previously treated adults whose multiple myeloma has returned and is resistant to treatment.
Eltrombopag olamine is a thrombopoietin-receptor agonist that stimulates bone marrow to make more platelets. Specialists use it for selected people with low platelet counts or severe aplastic anaemia.
Emicizumab is a bispecific monoclonal antibody used to prevent or reduce bleeding in haemophilia A. It provides factor VIII-like activity and can work whether or not factor VIII inhibitors are present.
Empagliflozin is a prescription SGLT2 inhibitor that makes the kidneys remove more glucose and sodium in urine. In the UK, it is licensed for type 2 diabetes, symptomatic chronic heart failure and chronic kidney disease in specified age groups.
This fixed-dose tablet combines empagliflozin, an SGLT2 inhibitor, with linagliptin, a DPP-4 inhibitor. It is used in selected adults with type 2 diabetes to improve blood glucose control.
A fixed-dose tablet combining an SGLT2 inhibitor with metformin. Alongside diet and exercise, it improves blood glucose control in people with type 2 diabetes when metformin-based treatment is insufficient.
Emtricitabine is a nucleoside reverse-transcriptase inhibitor used with other antiretrovirals to treat HIV-1. It reduces viral replication but does not cure HIV and should not be used alone for treatment.
A fixed-combination antiretroviral treatment for HIV-1. It reduces viral replication and helps control viral load, but does not cure HIV.
A fixed-combination antiretroviral treatment for selected adults with HIV-1 whose viral load and resistance history meet product-specific criteria.
This combination contains two antiretroviral reverse-transcriptase inhibitors. It is used with other antiretrovirals to treat HIV-1 and, within its licensed population, as pre-exposure prophylaxis (PrEP). It does not cure HIV.
This fixed-combination tablet contains two reverse-transcriptase inhibitors. It is used with other antiretrovirals to treat HIV-1, or as pre-exposure prophylaxis (PrEP) for people confirmed HIV-negative who are at high risk of acquiring HIV.
This fixed combination contains two reverse-transcriptase inhibitors. It is used with other antiretrovirals to treat HIV-1 and, in people confirmed HIV-negative, as pre-exposure prophylaxis (PrEP) alongside other prevention measures.
This fixed-combination antiretroviral is licensed for HIV-1 treatment as part of combination therapy and as PrEP to reduce sexually acquired HIV-1 risk in people confirmed to be HIV-negative.
This antiviral tablet combines two reverse-transcriptase inhibitors. It is licensed with other antiretrovirals to treat HIV-1 and as pre-exposure prophylaxis (PrEP) for people confirmed HIV-negative.
In the selected licensed aqueous cream, emulsifying ointment is combined with paraffins and water to moisturise dry skin. It can also replace soap for washing.
This water-containing emollient cream contains emulsifying ointment and paraffins. It relieves dry skin symptoms and can replace soap, although it may irritate some people when left on the skin.
This paraffin-based ointment contains recognised emollient ingredients. It is licensed for pharmacists to prepare Aqueous Cream BP and Buffered Cream BP, not with its own clinical indication or treatment schedule.
Enalapril maleate is an ACE inhibitor that relaxes blood vessels. It is used for high blood pressure and heart failure; a specific orodispersible product is licensed for heart failure in children.
This tablet combines an ACE inhibitor with a thiazide diuretic. It treats essential hypertension not adequately controlled by enalapril alone, or replaces the same components in someone already stabilised on them separately. It is not licensed as initial treatment.
Encorafenib is a targeted anti-cancer treatment that blocks abnormal BRAF signalling. In adults, it is used with other treatments for certain BRAF-mutated melanomas, colorectal cancers and non-small cell lung cancers.
Enfortumab vedotin is an antibody–drug conjugate that targets Nectin-4 and delivers a cell-killing agent into cancer cells. It is used for certain bladder and urothelial cancers, either with pembrolizumab or alone after specified previous treatments.
Enoxaparin sodium is a low molecular weight heparin anticoagulant given by injection. It helps prevent new blood clots and stops existing clots becoming larger.
Entacapone is a COMT inhibitor used alongside levodopa in adults with Parkinson’s disease. It prolongs levodopa’s effect and may reduce end-of-dose wearing off. It does not control symptoms when taken alone.
Entecavir is a nucleoside analogue antiviral used mainly to treat chronic hepatitis B. It reduces viral replication, helping to limit ongoing liver damage, but does not prevent transmission.
Entecavir is a nucleoside analogue antiviral used to treat chronic hepatitis B. It reduces viral replication and helps limit continuing liver damage, but does not eliminate transmission risk.
Entrectinib is an oral targeted cancer treatment that blocks abnormal kinase signals produced by certain NTRK or ROS1 gene changes. It is used only when testing confirms a relevant alteration and the cancer meets specific licensing criteria.
Enzalutamide is an anti-androgen treatment for prostate cancer. It blocks hormone signals that can help prostate cancer cells grow.
Epcoritamab is a bispecific antibody that brings T cells into contact with CD20-positive lymphoma cells so the immune system can destroy them. It is a specialist treatment for adults with certain relapsed or treatment-resistant B-cell lymphomas, given by injection under the skin.
Ephedrine hydrochloride stimulates adrenergic pathways. UK-licensed tablets prevent or relieve asthma-related bronchospasm, while injections reverse low blood pressure caused by spinal or epidural anaesthesia.
Epinastine hydrochloride is an anti-allergic eye treatment licensed in the UK for symptoms of seasonal allergic conjunctivitis, including itchy, red, watery or swollen eyes.
Epirubicin hydrochloride is an anthracycline chemotherapy that damages the DNA of rapidly dividing cells. It is given in hospital into a vein for several cancers or directly into the bladder for certain superficial bladder cancers.
Eplerenone is an aldosterone-blocking treatment used alongside other treatments for certain adults with heart failure, including after some heart attacks.
Eplontersen sodium is an antisense oligonucleotide that reduces transthyretin production in the liver. It is licensed for adults with stage 1 or stage 2 polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Erdafitinib is an FGFR tyrosine kinase inhibitor used for certain advanced urothelial cancers with susceptible FGFR3 genetic alterations after previous PD-1 or PD-L1 immunotherapy.
Eribulin mesilate is cytotoxic chemotherapy that disrupts structures cancer cells need to divide. In adults, it is used for certain previously treated advanced breast cancers and unresectable liposarcoma.
Esomeprazole magnesium trihydrate delivers esomeprazole, a proton pump inhibitor that reduces stomach-acid production. It treats reflux and several ulcer-related conditions. Some adult reflux products are available without prescription; broader uses require prescribing.
Eszopiclone is a prescription-only, non-benzodiazepine hypnotic known as a Z-drug. It is licensed for adults with insomnia that is severe, disabling or causing extreme distress.